Redcare Pharmacy’s Prescription Boom Faces a Profitability Reckoning

Redcare Pharmacy's Q1 revenue jumps 18.3% to €848M, but peak investment spending and margin cuts drag shares 60% below highs ahead of May 6 report.

Redcare Pharmacy is riding a wave of prescription drug demand that would make most online retailers envious, yet its stock is trading near levels that suggest investors see trouble ahead. The disconnect between surging sales and a battered share price sets the stage for a pivotal moment when the company releases its full first-quarter report on May 6.

The numbers from the opening quarter of 2026 tell a story of explosive growth. Group revenue climbed 18.3 percent to €848 million, beating analyst expectations. The prescription drug business in Germany — the crown jewel of Redcare’s operations — jumped 55 percent to €168 million, according to one set of figures, while another measure pegs the Rx segment at €315 million with 35 percent growth, driven by the electronic prescription boom. The non-prescription business added 10 percent to reach €533 million, hitting the top end of management’s own forecast.

That growth has a powerful tailwind from the bricks-and-mortar pharmacy world. Germany’s network of physical pharmacies shrank to just 16,601 by the end of 2025 — a drop of 440 from the prior year and roughly 20 percent fewer than in 2013. Every closure potentially funnels more prescription volume into digital channels, where Redcare already commands a 67 percent share of the German online prescription market.

The Margin Squeeze That Won’t Let Go

The catch is that Redcare is spending heavily to capture that growth. The company has declared 2026 its peak investment year, with a new logistics center in Pilsen, Czech Republic, set to boost annual capacity by 15 million packages. That spending is eating into profitability. Management has already slashed its medium-term margin target from above 8 percent to more than 5 percent, and for the full year 2026, it is guiding for an adjusted EBITDA margin of at least 2.5 percent.

The market has punished the stock accordingly. Shares are trading around €48, down more than 60 percent from the 52-week high of €136.20. The stock has lost roughly 29 percent since the start of the year, though it has recovered significantly from a March low of €31. The relative strength index sits at 19, signaling deeply oversold conditions.

A Political Wild Card That Could Change Everything

The German government is weighing a healthcare reform that could fundamentally alter Redcare’s competitive position. Health Minister Nina Warken (CDU) has finalized a draft law targeting €16.3 billion in savings — enough to cover the projected €15 billion deficit in the statutory health insurance system. The centerpiece for pharmacy customers: the minimum co-payment for prescription drugs would rise from €5 to €7.50, and the cap would increase from €10 to €15.

For online pharmacies, this creates a structural advantage. Felix Dennl, an analyst at Bankhaus Metzler, points to a European Court of Justice ruling that allows EU-based mail-order pharmacies to offer bonuses of between €2.50 and €20 on prescription orders — bonuses that can effectively offset the higher co-payments. Traditional pharmacies are barred from doing the same.

A government expert commission has also recommended raising statutory co-payments by 50 percent, reinforcing the direction of travel. The cabinet is expected to vote on the reform draft on April 29, and Warken aims to have it through parliament by the end of July.

Competition Heats Up on the OTC Front

While the prescription business enjoys structural protection, the over-the-counter segment is facing new threats. Drugstore chain dm has launched its own platform called “dm-med,” and Rossmann is planning a similar online pharmacy as a core project for this year — though without prescription medications.

That distinction matters. Redcare’s prescription business remains insulated from direct competition in a way its OTC operations are not. The company expects Rx revenue to exceed €670 million for the full year 2026.

What May 6 Will Reveal

The first-quarter report on May 6 will be the first major test for new Chief Financial Officer Hendrik Krampe. Investors want to see whether the revenue growth translates into sustainable earnings, or whether the investment cycle continues to weigh on margins.

Analyst sentiment remains surprisingly bullish despite the stock’s slide. Seven analysts rate the shares a buy, with none recommending a sell. The average price target stands at roughly €95 — nearly double the current level. Barclays has trimmed its target from €110 to €70 but maintains an “Overweight” rating.

The question hanging over Redcare is whether the political and market tailwinds can overcome the margin headwinds. The prescription boom is real, the competitive moat is widening, and the regulatory environment may soon tilt even further in the company’s favor. But the investment cycle has a cost, and the market is demanding proof that the payoff is coming.